港股開盤 | 恆指高開0.56%,PD-1概念股普漲,科技股繼續反彈
【三大指數】
恆生指數開盤上漲148.15點,漲幅0.56%,報26608.44點;
國企指數開盤上漲49.46點,漲幅0.47%,報10511.36點;
紅籌指數開盤下跌18.55點,跌幅0.5%,報3656.68點。
【新股首日】
上市首日,雲想科技平開,遠洋服務低開0.34%。
【異動板塊】
PD-1概念股普漲:信達生物高開3.11%、君實生物高開2.87%、百濟神州高開0.07%。
科技股繼續反彈:網易漲超2%,阿里、京東、美團、騰訊漲超1%。
【異動個股】
藥明生物高開5.85%,交銀國際看好研發能力強大的創新型生科企業,首選買入藥明生物。
信義光能低開3.16%,擬折讓6.7%配股籌39億。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.